Heron Bay Capital Management Grows Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Heron Bay Capital Management grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 152.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,269 shares of the biotechnology company’s stock after purchasing an additional 39,421 shares during the period. Heron Bay Capital Management’s holdings in Exelixis were worth $1,467,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Resonant Capital Advisors LLC increased its stake in Exelixis by 3.6% during the 2nd quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock worth $309,000 after buying an additional 477 shares during the period. Cornercap Investment Counsel Inc. increased its position in shares of Exelixis by 1.1% during the second quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock worth $1,135,000 after acquiring an additional 539 shares during the last quarter. Alaska Permanent Fund Corp lifted its stake in shares of Exelixis by 1.2% in the first quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company’s stock worth $1,263,000 after acquiring an additional 617 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 728 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in Exelixis by 11.5% during the 1st quarter. Banque Cantonale Vaudoise now owns 7,555 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 781 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research report on Wednesday, August 7th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, UBS Group assumed coverage on Exelixis in a report on Thursday. They issued a “neutral” rating and a $30.00 price objective for the company. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Insider Buying and Selling at Exelixis

In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares in the company, valued at $19,622,479.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares in the company, valued at approximately $19,622,479.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 20,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now directly owns 630,325 shares in the company, valued at $16,256,081.75. The disclosure for this sale can be found here. Insiders sold 302,858 shares of company stock valued at $7,980,629 in the last ninety days. Company insiders own 2.85% of the company’s stock.

Exelixis Price Performance

NASDAQ:EXEL opened at $26.42 on Friday. The firm has a market capitalization of $8.01 billion, a P/E ratio of 41.28, a P/E/G ratio of 0.58 and a beta of 0.54. The business has a 50 day simple moving average of $25.20 and a 200 day simple moving average of $23.35. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $27.83.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.44. The company had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. Research analysts anticipate that Exelixis, Inc. will post 1.54 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.